HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ZGN-1061

a methionine aminopeptidase 2 (MetAP2) inhibitor for treatment of obesity

Networked: 3 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 207
- 1-Ring Heterocyclic Compounds
  - Oxazines: 10
    - Morpholines: 7
      - ZGN-1061: 3
  - Azetines
    - Azetidines: 8
      - ZGN-1061: 3

Experts

1.	Colman, Peter G: 1 article (01/2020)
2.	Wentworth, John M: 1 article (01/2020)
3.	Zafgen Study Group: 1 article (01/2020)
4.	Burkey, Bryan F: 1 article (01/2018)
5.	Hoglen, Niel C: 1 article (01/2018)
6.	Hughes, Thomas E: 1 article (01/2018)
7.	Inskeep, Phil: 1 article (01/2018)
8.	Inskeep, Philip: 1 article (01/2018)
9.	Kim, Dennis: 1 article (01/2018)
10.	Kim, Terri: 1 article (01/2018)

Related Diseases

1.	Overweight 01/01/2020 - "We conclude that MetAP2 inhibition with ZGN-1061 for 12 weeks improved glucose control and aided weight loss in overweight and obese people with type 2 diabetes. " 01/01/2020 - "The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo-controlled trial."
2.	Type 2 Diabetes Mellitus (MODY) 01/01/2020 - "We conclude that MetAP2 inhibition with ZGN-1061 for 12 weeks improved glucose control and aided weight loss in overweight and obese people with type 2 diabetes. " 01/01/2020 - "The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo-controlled trial."
3.	Weight Loss (Weight Reduction) 01/01/2020 - "We conclude that MetAP2 inhibition with ZGN-1061 for 12 weeks improved glucose control and aided weight loss in overweight and obese people with type 2 diabetes. "
4.	Obesity 01/01/2018 - "Here, we report the pharmacological characterization of ZGN-1061, a novel MetAP2 inhibitor being investigated for treatment of diabetes and obesity. " 01/01/2018 - "In conclusion, ZGN-1061 and beloranib demonstrated similar efficacy in a mouse model of obesity, while ZGN-1061 had a markedly improved safety profile in multiple in vitro and in vivo models. "
5.	Headache (Headaches) 01/01/2018 - "ZGN-1061 was well tolerated across all doses, with the most frequent adverse events being mild headache and procedural-related irritation. "

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	CKD732
3.	methionine aminopeptidase 2
4.	Insulin (Novolin)